Cost-Effectiveness of Sacral Neuromodulation Versus Intravesical Botulinum A Toxin for Treatment of Refractory Urge Incontinence

Journal of Urology

Volumn 182, Issue 6, 2009, Pages 2799-2804

  Siddiqui, Nazema Y ^a   Amundsen, Cindy L ^a   Visco, Anthony G ^a   Myers, Evan R ^a   Wu, Jennifer M ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

botulinum toxins; cost benefit analysis; neurotransmitter agents; urinary incontinence, urge

Indexed keywords

BOTULINUM TOXIN A;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; MEDICAL DECISION MAKING; NERVE STIMULATION; NEUROMODULATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SACRUM; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; URGE INCONTINENCE;

ADMINISTRATION, INTRAVESICAL; BOTULINUM TOXINS, TYPE A; COST-BENEFIT ANALYSIS; ELECTRIC STIMULATION THERAPY; HUMANS; LUMBOSACRAL PLEXUS; MARKOV CHAINS; NEUROMUSCULAR AGENTS; URINARY INCONTINENCE, URGE;

EID: 71849119859     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.08.031     Document Type: Article

References (27)

1. Hu T.W., Wagner T.H., Bentkover J.D., et al. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology 63 (2004) 461
2. Brown J.S., Subak L.L., Gras J., et al. Urge incontinence: the patient's perspective. J Womens Health 7 (1998) 1263
3. Hijaz A., Vasavada S.P., Daneshgari F., et al. Complications and troubleshooting of two-stage sacral neuromodulation therapy: a single-institution experience. Urology 68 (2006) 533
4. Sahai A., Khan M.S., and Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 177 (2007) 2231
5. Rajkumar G.N., and Conn I.G. Botulinum toxin: a new dimension in the treatment of lower urinary tract dysfunction. Urology 64 (2004) 2
6. Brubaker L., Richter H.E., Visco A., et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 180 (2008) 217
7. Sonnenberg F.A., and Beck J.R. Markov models in medical decision making: a practical guide. Med Decis Making 13 (1993) 322
8. Borawski K.M., Foster R.T., Webster G.D., et al. Predicting implantation with a neuromodulator using two different test stimulation techniques: a prospective randomized study in urge incontinent women. Neurourol Urodyn 26 (2007) 14
9. Blandon R.E., Gebhart J.B., Lightner D.J., et al. Re-operation rates after permanent sacral nerve stimulation for refractory voiding dysfunction in women. BJU Int 101 (2008) 1119
10. Sutherland S.E., Lavers A., Carlson A., et al. Sacral nerve stimulation for voiding dysfunction: one institution's 11-year experience. Neurourol Urodyn 26 (2007) 19
11. Van Voskuilen A.C., Oerlemans D.J., Weil E.H., et al. Medium-term experience of sacral neuromodulation by tined lead implantation. BJU Int 99 (2007) 107
12. Hassouna M.M., Siegel S.W., Nyeholt A., et al. Sacral neuromodulation in the treatment of urgency-frequency symptoms: a multicenter study on efficacy and safety. J Urol 163 (2000) 1849
13. Siegel S.W., Catanzaro F., Dijkema H.E., et al. Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention. Urology 56 (2000) 87
14. Davis J.B. Medical Fees in the United States, 2008: Nationwide Charges for Medicine, Surgery, Laboratory, Radiology and Allied Health Services. 14th ed. (2008), Practice Management Information Corporation, Los Angeles
15. Centers for Medicare and Medicaid Services. http://www.cms.hhs.gov/FeeScheduleGenInfo Accessed April 15, 2008
16. Schultz S.E., and Kopec J.A. Impact of chronic conditions. Health Rep 14 (2003) 41
17. Subak L.L., Brubaker L., Chai T.C., et al. High costs of urinary incontinence among women electing surgery to treat stress incontinence. Obstet Gynecol 111 (2008) 899
18. Aboseif S.R., Kim D.H., Rieder J.M., et al. Sacral neuromodulation: cost considerations and clinical benefits. Urology 70 (2007) 1069
19. Schmid D.M., Sauermann P., Werner M., et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 176 (2006) 177
20. Rapp D.E., Lucioni A., Katz E.E., et al. Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience. Urology 63 (2004) 1071
21. Guralnick M.L., Benouni S., O'Connor R.C., et al. Characteristics of infections in patients undergoing staged implantation for sacral nerve stimulation. Urology 69 (2007) 1073
22. Spinelli M., Weil E., Ostardo E., et al. New tined lead electrode in sacral neuromodulation: experience from a multicentre European study. World J Urol 23 (2005) 225
23. Drugstore.com. www.drugstore.com Accessed April 15, 2008
24. Grosse J., Kramer G., and Stohrer M. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 47 (2005) 653
25. Karsenty G., Reitz A., Lindemann G., et al. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology 68 (2006) 1193
26. Gold M.R., Siegel J.E., Russell L.B., et al. Cost-Effectiveness in Health and Medicine (1996), Oxford University Press, New York
27. King Jr. J.T., Tsevat J., Lave J.R., et al. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med Decis Making 25 (2005) 667